HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note issued to investors on Monday. HC Wainwright currently has a $2.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the stock. Jefferies Financial Group reiterated a hold rating on shares of Celldex Therapeutics in a research note on Friday, August 10th. Cowen reiterated a hold rating on shares of Celldex Therapeutics in a research note on Thursday, August 9th. Finally, Zacks Investment Research cut shares of Celldex Therapeutics from a hold rating to a sell rating in a research note on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. Celldex Therapeutics currently has an average rating of Hold and a consensus target price of $3.75.

CLDX stock opened at $0.33 on Monday. Celldex Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.09.

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Celldex Therapeutics by 1.7% in the 1st quarter. BlackRock Inc. now owns 10,097,481 shares of the biopharmaceutical company’s stock worth $23,527,000 after acquiring an additional 166,780 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Celldex Therapeutics by 74.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,167,585 shares of the biopharmaceutical company’s stock worth $9,710,000 after acquiring an additional 1,783,765 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Celldex Therapeutics by 378.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock worth $583,000 after acquiring an additional 915,863 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Celldex Therapeutics by 27.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 900,185 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 195,147 shares during the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Celldex Therapeutics in the 2nd quarter worth about $206,000. Institutional investors own 33.42% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Featured Story: Ex-Dividend

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.